Navigation Links
Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy
Date:7/14/2014

Hicksville and Hauppauge, NY (PRWEB) July 14, 2014

The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment for diabetic macular edema (DME) patients. Ozurdex, a corticosteroid manufactured by Allergan, recently obtained an additional FDA-approved indication for use in diabetic macular edema. Ozurdex was previously approved by the FDA in 2009 for treatment of retinal vascular occlusions and and in 2010 for non-infectious uveitis (inflammation in the eye).

DME, a leading cause of vision loss in diabetic patients, is a condition in which microvascular damage from diabetes leads to leakage in the central portion of the retina, the macula. This causes blurring and loss of vision, and eventually legal blindness. The OZURDEX® biodegradable implant is delivered as an injection, and is administered during an office visit. The medication is slowly released over a period of months, suppressing inflammation, a key factor in DME. On average, patients receiving the medication demonstrate an improvement in vision and less leakage.

According to James M. Maisel, M.D., Chairman of the Retina Group of New York and a vitreoretinal surgeon, “Laser treatments and vitreous surgery have nearly eliminated the blinding complications of proliferative diabetic retinopathy for decades. However, over half a million diabetics with the background form of diabetic retinopathy develop diabetic macular edema (DME), threatening their fine vision, and their ability to read and drive. Precise focal laser treatment for DME typically only slowed visual loss. In 2010, Lucentis® was approved for treatment of DME and quickly became the standard of care, stabilizing or improving vision two lines in two years in about 1/3 of patients but often requiring monthly injections. We are thrilled to now have a second FDA-approved medication, Ozurdex, for treatment of DME,” Dr. Maisel continues. “The mechanism of action is different from Lucentis and it may act in concert for challenging cases with duration of action of up to six months.”

Rodney P. Coe, M.D., an associate retinal specialist with the Retina Group of New York, states that, “Our group has over 5 years of experience administering Ozurdex for treatment of posterior uveitis and retinal vascular occlusions. Ozurdex is administered in the eye during routine office visits and has proven to be safe and effective. Diabetic macular edema involves complex mechanisms, and having an additional treatment option broadens our ability to control this condition.”

For more information about Ozurdex treatment for DME, or to schedule a consultation with the Retina Group of New York, please call 516.939.6100 or 631-273-1818. An NIH video, "Diabetic Retinopathy" can be viewed on YouTube.

About The Retina Group of New York
The Retina Group of New York is composed of Board Certified Ophthalmologists with additional subspecialty training in vitreous and retinal surgery and medical retinal diagnosis and treatment. The group provides eye care for patients with retinal problems such as diabetic retinopathy, macular degeneration, retinal vascular disease, retinal detachments, vitreoretinal interface disorders such as VMA, macular puckers and holes, surgical complications, uveitis and second opinions. Members of the group holds staff privileges at seven area hospitals, teaching appointments and served as a Corporate Advisory Board member for the Foundation of the American Academy of Ophthalmology (AAO), the Juvenile Diabetes Foundation Medical Advisory Board and the AAO Instrument and Device and Low Vision Committees. They have received research grants from the U.S. Public Health Service and the National Institute of Health and represented the National Society to Prevent Blindness at the ANSI Z-80 committee helping to establish many ophthalmic industry standards.

Read the full story at http://www.prweb.com/releases/diabetic/retinopathy/prweb12008533.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Antibiotics Linked to Retinal Detachment Risk
2. Gene Signal presents data at ARVO 2012 showing topical aganirsen is active in retinal disease
3. New type of retinal prosthesis could better restore sight to blind, Stanford study says
4. Prosthetic retina offers simple solution to restoring sight
5. Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases
6. Retinal Device Restores Sight to Blind Mice
7. Retina Specialty Institute Gives Patients Something to Look Forward to in Crestview
8. UCIs Gavin Herbert Eye Institute receives $3 million for retinal degeneration research
9. San Antonio Eye Center Welcomes Retina Specialist Dr. Calvin Christopher Brown
10. Nationally-Recognized Retinal Expert Returns to Gainesville, Joins Retina Specialty Institute
11. Preferred retinal location may aid rehabilitation in patients with central vision loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... The ... announced it has signed a letter of intent with Moda to ... Insurance Company (NORDIC). , Started by dentists 36 years ago, TDIC focuses exclusively ...
(Date:4/28/2016)... ... April 28, 2016 , ... Head Over Heels Athletic ... Western Championships. The competition will be held at the University of Montana on April ... west of the Mississippi River. , In order to qualify, Varize needed to place ...
(Date:4/28/2016)... WASHINGTON, D.C., (PRWEB) , ... April 28, 2016 ... ... health systems, and the Campaign for Tobacco-Free Kids, a leading force in the ... to promote federal, state and local policies that can help reduce tobacco use. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Management solutions, announces today the availability of its latest software release, NetZoomDC ... capacity management and optimization, providing new analytical capabilities that assess complex capacity ...
(Date:4/28/2016)... ... April 28, 2016 , ... The American ... and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , ... Network. The platform is scheduled to launch in July 2016 and will be ...
Breaking Medicine News(10 mins):
(Date:4/26/2016)... -- US demand for infection prevention products and ... to $27.6 billion in 2020.  Increasing pressures on ... of healthcare-associated infections (HAIs) will boost revenues generated ... declining, the overall rate of certain HAIs in ... the CDC.  Recent statistics indicate that only 25 ...
(Date:4/26/2016)... April 26, 2016 Bayer AG ... interest, taxes, depreciation and amortization. The earnings are the ... multinational,s best-selling drugs Xarelto and Eylea, drugs Bayer is ... Xarelto,s patent expiration date was extended by four years ... market is expected to reach a value of ...
(Date:4/26/2016)... YORK , April 26, 2016 /PRNewswire/ ... report "Global Microbial identification Market Size, Share, ... - Industry Insights by Product (Consumables, Instruments ... Method and Genotypic Method), by Application (Diagnostic ... and Environmental Application) and by End User ...
Breaking Medicine Technology: